Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply
Aliment Pharmacol Ther
.
2022 Jan;55(2):253-254.
doi: 10.1111/apt.16724.
Authors
Jurij Hanzel
1
2
,
Laura H Bukkems
3
,
Krisztina B Gecse
1
,
Geert R D'Haens
1
,
Ron A A Mathôt
3
Affiliations
1
Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.
2
Faculty of Medicine, University of Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia.
3
Department of Hospital Pharmacy - Clinical Pharmacology, Amsterdam UMC, Amsterdam, the Netherlands.
PMID:
34970767
DOI:
10.1111/apt.16724
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal
Colitis, Ulcerative*
Crohn Disease* / diagnostic imaging
Humans
Infliximab
Substances
Antibodies, Monoclonal
CT-P13
Infliximab